Who we are
CBI is a central european human therapeutics company in the biotechnology industry that integrates a molecular biology platform with drug development and commercial expertise in discovering and developing disease therapy which targets specific genetic groups.
At CBI we are driven by our commitment to cutting-edge science as we attempt to develop bioactive molecule treatments that positively impact patients' lives.
We work with top European researchers, doctors, health experts and other partners who share our vision.
The company's leading specialists are experts in the field of cardiac disease- cell therapy, imaging of structural and functional changes and individual genomics for patients.
In 2011 we applied two forms for EU grant support as project partner:
IMI-JU-2011 with Comenius University in Bratislava, University Medical Center Groningen and Universität Mϋnster- "Molecular aspects of drug-induced heart failure and ventrcular arrythmias"
FP7-KBBE-2012-6 with Adexgo Ipari, University of Bologna, Universiteit Ghent, Campden BRI, Experimetria, SIK, Cadmos, Soya-Progres "Develop feeds and feed ingredients from food waste of dairy and plant origin"